Oruka Therapeutics, Inc.
ORKA
$41.48
-$0.27-0.65%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | ||
|---|---|---|---|---|---|
| Net Income | -15.44% | -- | -- | -- | |
| Total Depreciation and Amortization | 181.36% | -- | -- | -- | |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | |
| Total Other Non-Cash Items | 26.52% | -- | -- | -- | |
| Change in Net Operating Assets | -120.21% | -- | -- | -- | |
| Cash from Operations | -39.81% | -- | -- | -- | |
| Capital Expenditure | -1.36% | -- | -- | -- | |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | |
| Cash Acquisitions | -- | -- | -- | -- | |
| Divestitures | -- | -- | -- | -- | |
| Other Investing Activities | 73.18% | -- | -- | -- | |
| Cash from Investing | 73.14% | -- | -- | -- | |
| Total Debt Issued | -- | -- | -- | -- | |
| Total Debt Repaid | -- | -- | -- | -- | |
| Issuance of Common Stock | -62.97% | -- | -- | -- | |
| Repurchase of Common Stock | -- | -- | -- | -- | |
| Issuance of Preferred Stock | -- | -- | -- | -- | |
| Repurchase of Preferred Stock | -- | -- | -- | -- | |
| Total Dividends Paid | -- | -- | -- | -- | |
| Other Financing Activities | -- | -- | -- | -- | |
| Cash from Financing | -65.27% | -- | -- | -- | |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | |
| Net Change in Cash | -121.79% | -- | -- | -- | |